ASOcura
Latest round
- Series A
Last raised
- Jul 2024
Total raised
- $14M
Investors
- 2
About ASOcura
Established in 2017 and based in Suzhou, China, ASOcura operates as a small nucleic acid drugs developer that provides antisense oligonucleotide drugs. The company cooperates with Penguin Home. Yimin Hua, the founder of the company, was the principal inventor of Nusinersen. The company targets RNA splicing and RNA editing, and provides small nucleic acid drugs for patients with Duchenne muscular dystrophy (DMD) and spinocerebellar ataxia type 3 (SCA3). Products can alter the splicing signal sequence, orientation, and protein product of NA precursors. The company’s revenue is generated by providing small nucleic acid drugs.
Who invested in ASOcura
2 investors across 1 round
See all investors in ASOcura
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Jul 1, 2024
Amount
$14M
Investors
Questions about ASOcura
Who invested in ASOcura?
ASOcura has 2 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has ASOcura raised?
ASOcura has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did ASOcura last raise money?
ASOcura's most recent round on record is a Series A, in Jul 2024.
What does ASOcura do?
Established in 2017 and based in Suzhou, China, ASOcura operates as a small nucleic acid drugs developer that provides antisense oligonucleotide drugs.
Where is ASOcura headquartered?
ASOcura is headquartered in Suzhou, China.
Which VCs invest in companies like ASOcura?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back pharmaceuticals companies at ASOcura's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series A
Raising like ASOcura? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.